Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
303 Leser
Artikel bewerten:
(1)

Suvoda LLC: Suvoda Further Advances Mission to Reduce Friction in Complex Clinical Trials With Addition of Dr. Jill Platko as VP of Scientific Services

Leading industry veteran joins Suvoda to advance the company's eCOA product ahead of launch

PHILADELPHIA, July 12, 2022 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas such as oncology, central nervous system (CNS), and rare disease, today announced the hiring of Jill Platko, PhD as Vice President of Scientific Services. Suvoda has led the way in IRT (Interactive Response Technology) development for innovative trial designs, and the addition of Dr. Platko to its team will further Suvoda's commitment to supporting pharmaceutical and biotechnology companies throughout the entire clinical trial journey for complex, life-sustaining studies.

Jill Platko, Vice President of Scientific Services

Throughout her career, Dr. Platko has set a standard of excellence while working in challenging business and research settings and is adept at identifying opportunities for improvement through information systems and process optimization. In her role, Dr. Platko will actively collaborate with leadership to drive Suvoda's Scientific Consulting practice, partnering with sales and services to ensure customers are set up for success with Suvoda's eCOA (electronic Clinical Outcome Assessment) product - a solution on Suvoda's platform that makes it easier for patients to report critical outcome data, currently in the early adopter phase. Dr. Platko will review the clinical protocol with customers and provide both scientific and clinical guidance on Suvoda's design and implementation.

Dr. Platko joins Suvoda after serving as Senior Scientific Advisor at Signant Health, where she consulted with business development, project delivery, and product development teams and with clients with respect to eCOA systems for clinical trials.

"We are delighted to have Jill join our team. She is an accomplished leader in eCOA design and implementation with a record of success directing multi-disciplinary teams to design innovative applications that support science-based projects, including laboratory information system management and clinical research systems," said Robert Hummel, Chief Operating Officer of Suvoda. "Her combination of scientific, clinical, and information technology expertise will only reinforce Suvoda's ability to deliver cutting-edge solutions designed to manage the increasing complexity of global clinical trials."

Prior to Signant Health, Dr. Platko worked as the Associate Director of Global Health Economics and Outcomes Research at LabCorp Drug Development (formerly Covance), where she provided scientific consultation and support for projects collecting eCOA. She earned her PhD in genetics and development from Cornell University.

"I'm thrilled to have joined Suvoda just as the eCOA product is ready for early adopters," said Dr. Platko. "Rather than cobbling products together, Suvoda has built a single platform where eCOA, IRT, and eConsent all talk to each other and operate seamlessly. This unique approach underscores Suvoda's commitment to quality, and to me, that's exciting for the future of clinical trials."

About Suvoda
Suvoda is a global clinical trial technology company that specializes in complex, life-sustaining studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease. Founded in 2013 by experts in eClinical technologies, Suvoda empowers clinical trial professionals to manage the most urgent moments in the most urgent trials through advanced software solutions delivered on a single platform. Headquartered outside Philadelphia, Suvoda also maintains offices in Portland, OR, Barcelona, Spain, Bucharest, Romania and Tokyo, Japan. The company consistently boasts a Net Promoter Score (NPS) of close to 70, far exceeding the technology industry average of 50, and has been selected by trial sponsors and CROs to support more than 1000 trials across 65 countries. To learn more, visit suvoda.com. Follow Suvoda on Twitter and LinkedIn.

Media contact:
Morgan Reese
Clyde Group
morgan.reese@clydegroup.com

Suvoda

Photo - https://mma.prnewswire.com/media/1855522/Suvoda_LLC_Jill_Platko_VP_of_Scientific_Services.jpg

Logo - https://mma.prnewswire.com/media/1759317/Suvoda_Logo.jpg

© 2022 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.